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Abstract Cardiac fibrosis is one of the most devastating ef-
fects of cardiac disease. Current in vitro models of cardiac
fibrosis do not sufficiently mimic the complex in vivo envi-
ronment of the cardiomyocyte. We determined the local com-
position and mechanical properties of the myocardium in
established mouse models of genetic and acquired fibrosis
and tested the effect of myocardial composition on cardio-
myocyte contractility in vitro by systematically manipulating
the number of fibroblasts and collagen concentration in a plat-
form of engineered cardiac microtissues. The in vitro results
showed that while increasing collagen content had little effect
on microtissue contraction, increasing fibroblast density
caused a significant reduction in contraction force. In addition,
the beating frequency dropped significantly in tissues
consisting of 50% cardiac fibroblasts or higher. Despite ap-
parent dissimilarities between native and in vitro fibrosis, the
latter allows for the independent analysis of local determinants
of fibrosis, which is not possible in vivo.
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Introduction
The heart consists of cardiomyocytes, fibroblasts, and other
cardiac cells that are supported by a complex meshwork of
fibers, the cardiac extracellular matrix (ECM). In case of car-
diac disease, the heart is subject to changes in composition and
structure, often leading to cardiac fibrosis. While at first,
fibrogenesis is an effective mechanism of tissue repair, ongo-
ing adverse remodeling will lead to a decrease in cardiac func-
tionality and eventually to the development of heart failure
[1]. To halt or reverse this process, anti-fibrotic therapies are
being developed [2], so far with limited success, due to the
fact that the extent and distribution of fibrosis vary according
to the underlying pathology. Furthermore, there is a lack of
knowledge about the effects of fibrosis at the cellular level [3].
Engineered cardiac tissues are excellent models to mimic and
study normal and diseased cardiac development and physiol-
ogy and therefore open new avenues for therapy assessment.
The tissues can be cultured under highly controlled conditions
and give insights into the responses of cells and ECM on
isolated biochemical and biophysical stimuli, which would
be impossible to study in vivo. To apply such tissue models
as therapy screening platforms, it is important that the models
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accurately resemble the in vivo characteristics of the disease
and that in vitro results correlate with in vivo outcomes [4].
To our knowledge, no engineered tissue model of cardiac
fibrosis has been reported that takes into account this in vivo
to in vitro translation. Therefore, we aimed to develop an
engineered microtissue platform that mimics various aspects
of cardiac fibrosis based on the analysis of two well-
established mouse models of cardiac fibrosis having either a
genetic or an acquired cause of cardiac disease. By comparing
the in vitro outcomes to the native situation, strengths and
weaknesses of such disease models could be identified.
Current engineered cardiac disease models mainly incorpo-
rate genetically affected cells to capture a cardiac disorder [5,
6]. These models primarily focus on intrinsic problems of the
cardiomyocytes, while for cardiac fibrosis, the ECM and the
cardiac fibroblasts are of critical importance. To date, only few
in vitro models of cardiac fibrosis have been developed [7–9].
Unfortunately, most of these models are 2D co-cultures and
thus lack the important 3D environment of a fibrotic ECM [7,
8]. For cardiac cells, it has been shown that 3D cultures more
closely mimic natural tissue environments compared to 2D
cultures, resulting in different outcomes of proliferation, at-
tachment to the ECM and maturation in 2D compared to 3D
cultures [10]. Galie et al. [9] cultured cardiac fibroblasts in a
3D collagen gel to investigate the paracrine effect of mesen-
chymal stem cell injection in a scar tissue. Although ECMwas
incorporated in this model of fibrosis, cardiomyocytes were
lacking. Our engineeredmicrotissues include cardiomyocytes,
cardiac fibroblasts, and ECM, since all are affected by fibrosis.
Cardiac fibrosis is generally referred to as an increase in the
number of fibroblasts in the heart which lead to the excessive
production and deposition of several extracellular matrix pro-
teins, mainly collagen type I. Yet, different forms of fibrosis
can be recognized, which all have their own characteristics.
Reactive fibrosis, for instance, has mostly been described
in patients with hypertension and diabetes mellitus, but is also
present in the aging heart and in hearts suffering from pressure
overload. An important characteristic of this type of fibrosis is
the interstitial increase in ECM content and absence of cell
loss [11, 12]. Replacement or scarring fibrosis on the contrary
corresponds to the local replacement of cardiomyocytes by
fibrosis after cell death, for example after myocardial infarc-
tion [11, 12].
Due to this diversity, cardiac fibrosis is such a complex
condition that the relative importance of all different aspects
that play a role cannot be studied at once. Therefore, our
microtissue platform allows for the independent analysis of
different aspects of fibrosis, hence mimicking a variety of
cardiac fibrotic pathologies.
Mechanical properties, as well as composition of the ECM
of the twomouse models for cardiac pathologies accompanied
with fibrosis, were analyzed to obtain detailed in vivo aspects.
Although multiple mouse models for cardiac disease are
available in this study, the mdx and TAC model were chosen
because the origin and development of fibrosis in these two
models is different. Secondly, both mouse models are fre-
quently described in literature and often used to test anti-
fibrotic therapies [12–16]. The mdx mouse was chosen as a
model of genetic cardiac disease [17, 18], while a mouse
model with transverse aortic constriction (TAC) was chosen
to represent acquired heart disease [19]. Both mouse models
are known to develop cardiac fibrosis, based on general his-
tological methods for collagen assessment [15, 17].
Mechanical properties as well as localization, spatial distribu-
tion, and composition of the fibrotic areas in the heart were
determined and used as input for the in vitro tissue model.
Secondly, since activation and proliferation of fibroblasts is
a well-known contributor of cardiac fibrosis, especially after
TAC [20, 21], increase in fibroblast number was also incorpo-
rated as aspect of fibrosis. To this end, mouse neonatal cardiac
cells were cultured in engineered cardiac microtissues [22]. To
mimic various aspects of fibrosis, either the collagen content
or the number of cardiac fibroblasts was systematically in-
creased. Mechanical properties and matrix composition of
the in vitro microtissues were quantified and compared to
the obtained in vivo dataset. Contraction force and beating
frequency of the cardiac microtissues were determined to
study the correlation between fibrosis and cardiac contractile
function.
In this tunable microtissue platform based on in vivo as-
pects of fibrosis, both the increase of collagen content and
fibroblast number that occur with development of cardiac fi-
brosis were mimicked independently. The in vitro results
showed that while increasing collagen content had little effect
on microtissue contraction, increasing fibroblast density
caused a significant reduction in contraction force. In addition,
the beating frequency dropped significantly in tissues
consisting of 50% cardiac fibroblasts or higher. Hereby, we
were able to show that increased fibroblast density has a more
detrimental effect on cardiomyocyte contractile function than
accumulation of collagen. Furthermore, this model system can
be easily adapted to mimic different stages and forms of car-
diac fibrosis and thereby opens new opportunities for devel-
opment of effective anti-fibrotic treatments.
Methods
Preparation and Analysis of Cardiac Tissue from TAC
and mdx Mouse Models
C57Bl/10ScSnJ (control) and mdx (C57Bl/10ScSn-DMDmdx/
J) male mice at 10 months were sacrificed by cervical dislo-
cation and hearts were isolated [17, 18]. TAC hearts were
excised 9 weeks after surgery as well as the hearts from age
matched male controls (C57BL/6). Cardiac tissue was then
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processed for further analysis of mechanical properties and
tissue composition as outlined in the supplementary material.
In Vitro Microtissue Seeding and Analysis
Mouse neonatal cardiomyocytes and cardiac fibroblasts were
isolated from 1- to 3–day-old C57/BL6 mouse hearts as de-
scribed before [22, 23], and most cardiac fibroblasts were
removed to obtain an enriched cardiomyocyte population.
Further details are provided in the supplementary material.
Microfabricated tissue gauges (μTUG) with microposts as
uniaxial tissue constraints were fabricated using soft lithogra-
phy [22, 24]. To create microtissues with increasing fibroblast
density, hydrogel composition was the same as described pre-
viously [22], resulting in a final collagen concentration of
1.6 mg/ml. For microtissues with increasing collagen concen-
tration, the final concentration was varied between 0.5, 1.5,
2.5, and 3.5 mg/ml collagen type I. For both groups, cells were
trypsinized and suspended in the hydrogel at a concentration
of 1 × 106 cells/ml. For microtissues with increasing collagen
content, only enriched cardiomyocytes were used, while for
microtissues with extra cardiac fibroblasts, this cell suspen-
sion consisted of enriched cardiomyocytes mixed with 0, 15,
30, and 45% cardiac fibroblasts. At different time points,
microtissues were processed for further analysis of mechani-
cal properties, composition, and contractility as described in
the supplementary material.
Results
Composition and Mechanical Properties of Patchy
Fibrosis in mdx and TAC Mouse Hearts
To obtain an overview of the degree of fibrosis that was
developed in the mdx and TAC hearts, picrosirius red
staining was performed. Histological analysis showed that
collagen was present throughout the whole heart of mdx
mice (Fig. 1a–f, i–n). Most severe fibrosis was observed
in the entire right ventricle. Interestingly, in the left ven-
tricle, only patches of interstitial fibrosis were observed.
Furthermore, semi-quantitative image analysis revealed a
significantly larger area of collagen present in mdx hearts
compared to healthy hearts (1.8× higher) (Fig. 1c). For the
left ventricle alone, the collagen area of mdx left ventri-
cles was 1.7× larger than in healthy left ventricles
(Fig. 1g).
Histological analysis of hearts from mice 9 weeks after
TAC showed perivascular fibrosis and patchy interstitial fibro-
sis. Patchy fibrosis was especially found in the left ventricle
and ventricular septum, while the right ventricles seemed nor-
mal. 4.8× more collagen was found in TAC left ventricles
compared to healthy left ventricles (Fig. 1k).
To check whether this local increase of collagen detect-
ed with histology also affected total collagen content, a
HYP assay was performed. Whole hearts of mdx mice
contained 1.6× more HYP per milligram dry weight of
tissue when compared to hearts of healthy mice, although
this was not significantly different (Fig. 1d). Furthermore,
no significant differences in the amount of HYP were
found in the left ventricles of mdx mice when compared
to healthy ventricles (Fig. 1h). Similarly, for the left ven-
tricles of TAC hearts, a non-significant increase of HYP
was found, with 1.6× more HYP per milligram dry weight
of tissue in TAC left ventricles when compared to control
left ventricles (Fig. 1l).
Immunohistological analysis for collagen I and III and fi-
bronectin was performed on the fibrotic areas of bothmdx and
TAC left ventricles. Fibrotic patches in mdx left ventricles
showed presence of collagen I and III and fibronectin
(Fig. 2a–f). In contrast, the fibrotic areas of TAC left ventricles
showed only presence of collagen I and not of collagen III or
fibronectin (Fig. 3a–f).
To determine if the formation of these patchy areas of fi-
brosis affected the stiffness of the myocardium, indentation
tests were performed on tissue samples of the left ventricle.
Young’s modulus of mdx left ventricles (9.4 ± 2.6 kPa) was
significantly lower than healthy left ventricles (12.4 ± 4.5 kPa)
(Fig. 2g), while the stiffness of the right ventricle was not
significantly different between mdx (10.8 ± 3.6 kPa) and con-
trol hearts (11.9 ± 3.1 kPa) (Fig. 2h). For the TAC hearts,
Young’s modulus of the left ventricles (8.2 ± 2.7 kPa) was
not significantly different when compared to healthy left ven-
tricles (11.1 ± 7.4 kPa) (Fig. 3g).
In Vitro Tissue Model of Cardiac Fibrosis
The different features of cardiac fibrosis were mimicked
by manipulating the number of fibroblasts (referred to as
FB fibrosis) or the collagen concentration (referred to as
ECM fibrosis) in cardiac microtissues seeded in a previ-
o u s l y d e v e l o p μTUG sy s t em [ 22 ] . En r i c h e d
cardiomyocytes were used to create cardiac microtissues
for the FB control group, resulting in tissues with
68 ± 5% cardiomyocytes and 32 ± 5% cardiac fibroblasts
(Fig. 4a). These numbers were achieved by counting sar-
comeric α-actinin positive cardiomyocytes and vimentin-
positive cardiac fibroblasts. To increase fibroblast density,
cardiac fibroblasts from a previous isolation were added
to the enriched cardiomyocytes, resulting in microtissues
with a range of fibroblast densities. Next to the FB control
group with 32 ± 5% fibroblasts, adding extra fibroblasts
resulted in microtissues with 42 ± 6, 62 ± 7, and 66 ± 8%
fibroblasts, which are further referred to as the low, me-
dium, and high FB fibrosis group respectively (Fig. 4a).
Increasing the number of fibroblasts affected the
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compaction of the microtissues. The control group
compacted by 52 ± 4%, while adding extra fibroblasts
significantly increased the compaction up to 64 ± 2%
for the high FB fibrosis group (Fig. 4b). After 7 days of
culture, cardiac microtissues of the FB control group
showed presence of co l lagen I throughout the
microtissues and also around the nuclei of both
cardiomyocytes and fibroblast (Fig. 4d). Although no ex-
ogenous collagen III and fibronectin were added, both
matrix components were homogeneously distributed
throughout the microtissues and were also present in the
cytoplasm of both cell types (Fig. 4e, f). Fibronectin was
predominantly present in the cytoplasm of sarcomeric α-
actinin-negative fibroblasts (Fig. 4f). To verify if the in-
crease in cardiac fibroblasts also affected matrix compo-
sition, microtissues of the high FB fibrosis group were
also analyzed for presence of collagen I and III and fibro-
nectin (Fig. 4g–i). The high FB fibrosis group contained
much more fibroblasts than the control group, as indicated
by the decrease in sarcomeric α-actinin-positive cells
(Fig. 4i). However, the increase in cardiac fibroblasts
did not result in changes in the presence of collagen I
and III and fibronectin between the control and high FB
fibrosis groups (Fig. 4d–i). Stiffness of the different tissue
compositions of all four FB fibrosis groups was deter-
m ined by i nden t a t i on . Young ’s modu lu s was
Fig. 1 Myocardial fibrosis in mdx and TAC mouse hearts. Low-power
photomicrographs of picrosirius red-stained sections of healthy (a) and
mdx (e) transgenic hearts from mice aged 10 months and healthy (i) and
TAC hearts 9 weeks after constriction (m) show patchy fibrosis in both
disease models. Enlargement pictures of healthy (b, j) and fibrotic myo-
cardium (f, n). Bar graphs represent areas of collagen (%) determined
from the picrosirius red staining of the whole heart (c) and left ventricle
(g, k) and show a significant increase of collagen for both disease models.
Hydroxyproline content is not significantly different between healthy and
diseased whole heart (d) or left ventricle (h, l). Scale bar a/e/i/
m = 1000 μm and b/f/j/n = 100 μm. **P < 0.01 and ***P < 0.001
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3.9 ± 0.3 kPa for the FB control group and did not show
significant changes for tissues with increasing fibroblast
content (Fig. 4c).
Next to manipulating the fibroblast content of the cardiac
microtissues, we also varied the collagen concentration of the
microtissues to mimic fibrosis. Increased collagen concentra-
tion was accompanied by a reduction in compaction of the
tissues. The low ECM fibrosis group compacted for
67 ± 5% and increasing collagen concentration reduced the
compaction to 47 ± 5% for the high ECM fibrosis group
(Fig. 5a). Stiffness of the ECM control group was
4.0 ± 0.4 kPa and did not significantly change for tissues with
increasing collagen concentration (Fig. 5b).
Contractility of Fibrotic Cardiac Microtissues
Beating frequency and dynamic contraction force of the
microtissues were measured to study the effect of both FB
and ECM fibrosis on cardiomyocyte contractility sepa-
rately. Dynamic contraction force was determined at
Fig. 2 Matrix composition and
stiffness of healthy and mdx
hearts. Representative pictures of
myocardial tissue of healthy and
mdx left ventricles show
accumulation of collagen I (a, b)
collagen III (c, d) and fibronectin
(e, f) in the fibrotic areas. Nuclei
are stained in blue with DAPI.
Left ventricular stiffness of mdx
hearts is significantly lower than
healthy hearts (g), while stiffness
is not significantly different
between healthy and mdx right
ventricles (h). Scale bar = 50 μm.
*P < 0.05
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2.0 ± 1.1 μN for the FB control group and reduced to
1.3 ± 0.8 μN for the low FB fibrosis group, although this
decrease was not significant (Fig. 6a). Interestingly, fur-
ther increase in fibroblast density did cause a significant
decrease in contraction force to 0.5 ± 0.4 μN (medium FB
fibrosis) and 0.1 ± 0.3 μN (high FB fibrosis), resulting in
almost no contraction of microtissues in the high FB fi-
brosis group (Fig. 6a). Next to contraction force, beating
frequency is also an important indicator of contractility.
Beating frequency of the FB control group was
2.2 ± 0.7 Hz. For the low FB fibrosis group, beating
frequency was not significantly affected. However, beat-
ing frequency of the medium and high FB fibrosis group
significantly reduced to 1.0 ± 0.9 and 0.3 ± 0.5 Hz. The
fact that the beating frequency only decreased for the me-
dium and high FB fibrosis group raised the suggestion of
a threshold in fibroblast density above which beating of
the microtissues is drastically reduced. Indeed, analysis of
Fig. 3 Matrix composition and
stiffness of healthy and TAC
hearts. Presence of collagen I (a,
b) but not of collagen III (c, d) and
fibronectin (e, f) is shown in
representative pictures of fibrotic
areas of in the myocardial tissue.
Nuclei are stained in blue with
DAPI. Left ventricular stiffness is
not significantly different
between healthy and TAC hearts
(g). Scale bar = 50 μm
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frequency and fibroblast percentage of each individual
microtissues showed a clear threshold at 50% cardiac fi-
broblasts, above which the average beating frequency
dropped significantly. Microtissues with less than 50%
fibroblasts had an average frequency of 2.3 ± 0.9 Hz with
only 8% non-beating tissues compared to 0.6 ± 0.9 Hz
with 62% non-beating tissues for microtissues with more
than 50% cardiac fibroblasts (Fig. 6b).
By increasing the collagen concentration of the
microtissues, another aspect of cardiac fibrosis was
mimicked. Surprisingly, increasing collagen content had
no effect on contraction force or beating frequency
(Fig. 6c, d). Contraction force was similar for all four
groups (Fig. 6c). Beating frequency of the microtissues
fluctuated between 1.9 ± 0.9 and 2.7 ± 0.7 Hz with
significant differences but no increasing or decreasing
trend (Fig. 6d). This implies that the cardiomyocytes
were still able to exert the same force of contraction,
even though there was more collagen in between neigh-
boring cells.
Fig. 4 Cellular and matrix composition, compaction and stiffness of FB
fibrosis microtissues. Increasing fibroblast percentage (a) was confirmed
using immunohistochemistry markers for cardiomyocytes (α-actinin) and
cardiac fibroblasts (vimentin). Compaction of the microtissues increased
with increasing FB fibrosis (b). Stiffness remained constant for increasing
fibroblast number (c). Representative pictures of control and FB fibrosis
microtissues show homogeneous distribution of collagen I (d, g), collagen
III (e, h) and fibronectin (f, i) in all microtissues. Fibronectin is
predominantly present in the cytoplasm of sarcomeric α-actinin (green)
negative cells (f, i). Error bars for fibroblast percentage and compaction
represent SD of N ≥ 30 from three independent experiments. Error bars
for E-modulus represent nine measurement spots on three samples in one
experiment. Scale bar = 10 μm (d–i). *P < 0.05
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Discussion
Cardiac Fibrosis in mdx and TAC Mouse Hearts
Histological analysis confirmed the presence of fibrosis in
hearts frommice with both genetic and acquired heart disease.
Inmdxmice, fibrosis in the left ventricle was characterized by
a patchy distribution whereas fibrosis was homogeneously
distributed throughout the entire right ventricle. In earlier stud-
ies, patchy fibrosis was shown to affect all regions of the left
and right ventricle approximately equal [25], while others de-
scribed fibrosis in mdx hearts for the whole heart or left
ventricle only, thereby omitting conclusions about the distri-
bution pattern [17, 18, 26]. Current detailed analysis of the
fibrotic lesions showed presence of collagen I and III as well
as increased expression of fibronectin. While increase in fi-
bronectin in fibrotic areas is well documented in skeletal mus-
cle and diaphragms of mdx mice [27], to our knowledge, this
is the first time that the presence of fibronectin in fibrotic
lesions inmdx hearts is described. In TAC hearts, perivascular
fibrosis and interstitial patchy fibrosis was observed through-
out the left ventricle. Patchy fibrosis was previously described
from 16 weeks onwards after TAC, while at earlier time
points, only diffuse fibrosis was reported [28, 29].
Fig. 6 Effect of FB and ECM
fibrosis on microtissues
contractility. Contraction force
corrected for compaction (a)
decreased with increasing FB
fibrosis. A threshold of 50%
cardiac fibroblasts was found
(indicated by the red line) after
which beating of the FB fibrosis
microtissues was severely
hampered (b). On the contrary,
ECM fibrosis had little effect on
microtissues contractility.
Corrected contraction force was
similar for all ECM fibrosis
groups (c). Beating frequency
fluctuated but showed no
increasing or decreasing trend (d).
Error bars represent SD ofN ≥ 30
from three independent
experiments. *P < 0.05
Fig. 5 Compaction and stiffness of ECM fibrosis microtissues.
Compaction of the microtissues decreased with increasing collagen
concentration (a), while stiffness remained constant (b). Error bars for
compaction represent SD of N ≥ 40 from three independent experiments.
Error bars for E-modulus represent nine measurement spots on three
samples in one experiment. *P < 0.05
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Although immunohistochemistry revealed presence of fi-
brosis for both mdx and TAC hearts, biochemical analysis of
HYP did not show any increase in collagen content. The con-
tradiction in this data might be related to the sensitivity of both
techniques. HYP is a major component of collagen, but only
comprises 13.5% of the amino acid composition [30–32]. This
leads to lower total collagen content verified when using bio-
chemical assays since the affinity is less. Picrosirius red on the
other hand binds with high affinity to the triple helix structure
found in all collagen fibers leading to an over-estimate of the
total amount of collagen [32], especially when patchy fibrosis
is present. Another explanationmight be related to the fact that
this biochemical assay is a global measure while there is only
an increase in collagen in the fibrotic patches and not in the
rest of the hearts.
It is generally assumed that accumulation of ECM compo-
nents increases tissue stiffness. Surprisingly, indentation tests
showed no differences in ventricular stiffness for TAC hearts
and a significant decrease in left ventricular stiffness of mdx
hearts, even though patches of fibrosis with an increase in
matrix proteins are detected in the left ventricle. However,
for skeletal muscle lower Young’s moduli have been reported
for mdx mice when compared to healthy mice [33, 34]. This
decrease in stiffness could be attributed to loss of actin fila-
ments and/or microtubules [30], or cardiomyocyte death [35].
Collapse of the ECM due to cardiomyocyte death may result
in patchy fibrosis even though there is no real increase in
matrix proteins and thereby no increase in myocardial
stiffness.
Cardiac Fibrosis Mimicked in Engineered Microtissues
A homogeneous distribution of collagen I, collagen III, and
fibronectin was found in control microtissues and after 7 days
of culture ECM components were also expressed in the cyto-
plasm of the cardiac cells. Furthermore, microtissues from the
high FB fibrosis group showed the same distribution of these
proteins and no increase or decrease could be observed.
Previous work by Kelm et al. characterized the matrix of
myocardial microtissues from primary neonatal mouse
cardiomyocytes in hanging drop cultivations and showed
presence of fibronectin but absence of collagen I after 7 days
in culture [36]. The absence of collagen I in these purified
mouse cardiomyocyte cultures was explained as the predom-
inant production of collagen I by fibroblasts [36].
Changing tissue properties such as the cardiomyocyte/
fibroblast ratio or the collagen content could also affect the
mechanical properties of the cardiac microtissues. For native,
cardiac tissue is has been shown that the stiffness varies be-
tween healthy and infarct areas of the myocardium [37]. Some
studies assumed that tissue stiffness increases when collagen
content increases [38], which is contradicted by our results
that show similar Young’s moduli for all groups. However,
recently it has been shown that not collagen content but col-
lagen cross-linking determines tissue stiffness [39, 40]. Due to
the short culture time, we assume that cross-linking in our
microtissues is still limited and therefore will not affect tissue
stiffness. This is in line with previous research by Smith et al.
who showed that increased collagen content without increased
cross-linking density did not affect tissue stiffness [39].
Another explanation for this surprising result might be related
to the fact that indentation in this study was essential to per-
form non-destructive mechanical characterization of the living
cell containing microtissue while being attached to the
microposts. The cells compacted the hydrogels thereby con-
tributing to overall cell-gel construct density and stiffness,
especially in the uniaxial constrained configuration on our
micropost system. This contribution may have overruled the
change in collagen concentration.
Although in vitro tissue models are always a simplified
version of the native complexity, it is important to include
the most important building blocks of the tissue and the spe-
cific characteristics of the disease of interest. Therefore, our
microtissue model consists of an ECM containing hydrogel
with a mixture of cardiomyocytes and cardiac fibroblasts. In
our in vitro model of cardiac fibrosis, only an increase of
collagen type I was mimicked as observed in the fibrotic
patches of TAC hearts. Mdx hearts also showed patchy fibro-
sis in the left ventricle with increased collagen I, but also
collagen III and fibronectin were increased. Off course, exog-
enous collagen III and fibronectin could be added to the hy-
drogel composition to increase the resemblance to the native
situation. There is still a mismatch between the mechanical
properties of the in vitro model and the native mouse hearts.
The mouse hearts are at least twice as stiff as the microtissues.
Stiffness of the microtissues could be increased by increasing
the cross-linking density with transglutaminase [41], a process
that also happens in vivo with aging of the heart [42] or by
changing composition of the hydrogel by adding other matrix
components.
Fibroblast Density Rather than Collagen Content
Weakens Cardiomyocyte Contractile Function
In cardiac fibrosis, synchronized beating of the heart is often
hampered. However, it remains unclear how fibroblast prolif-
eration and accumulation of matrix influence cardiac contrac-
tility on the cellular level. Next to the synthesis of ECM,
cardiac fibroblasts play an important role in the maintaining
of normal cardiac functions. The fibroblasts also play an im-
portant role in cell-cell communication not only with
cardiomyocytes but also with endothelial cells and other fibro-
blasts. These contacts play an important role in electrophysi-
ological properties, in secretion of cytokines and growth fac-
tors, and in matrix regeneration and degradation under influ-
ence of the production metalloproteinases and their inhibitors
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[43]. Therefore, cardiomyocyte functionality was assessed by
measuring dynamic contraction force and beating frequency
of the microtissues representing the different aspects of fibro-
sis. Our results demonstrated a significant decrease in beating
frequency when the number of fibroblasts increased. This cor-
relates with previous 2D research, which demonstrated a de-
creased conduction velocity with increased fibroblast prolifer-
ation [44]. Furthermore, studies by others have shown that
fibroblasts can electrically connect to cardiomyocytes via
gap junctions [45, 46]. Although the gap junction protein
connexin43 was present in all cardiac microtissues, the 3D
distribution was random and not organized as in intercalated
disks (data not shown). Therefore, our results could not be
directly linked to gap junction formation between
cardiomyocytes and fibroblasts. Nevertheless, in 2D, it was
shown that cardiomyocytes beat much faster when cultured on
fibroblasts devoid of connexin43 than onwild-type fibroblasts
that do express these gap junction proteins [47]. Although it
has frequently been reported that fibroblast proliferation in-
hibits the contractility of cardiomyocytes, here, we demon-
strated a threshold value of 50% fibroblasts above which syn-
chronized beating was severely hampered.
Mimicking cardiac fibrosis by increasing collagen content of
the microtissues, surprisingly, showed no effect on contraction
force or beating frequency. This implies that the cardiomyocytes
were still able to exert the same force of contraction, even though
there was more collagen in between neighboring cells. These
results might be explained by the fact that only collagen content
but probably not the cross-linking density was increased and
therefore did not affect tissue stiffness [39].
By separately increasing collagen content and fibroblast
density in our in vitro model of cardiac fibrosis, we were able
to show that fibroblast density has a more destructive influ-
ence on cardiomyocyte contraction than collagen content.
Limitations and Future Perspectives
Themicrotissue platform described in this study is designed to
expand our knowledge about clinically relevant problems re-
garding myocardial fibrosis and improve currently available
therapies. However, translating observations from a microm-
eter scale cardiac tissue towards a four-chambered heart or
even the other way around has its limitations. Differences in
measurement techniques complicate correlating the outcomes
of in vitro and in vivo studies. Although, in this study,
microtissues were created with a ratio of cardiomyocytes to
fibroblasts which closely mimics the native tissue composi-
tion, changes in cell density or total number of cells present in
the gel will influence cell behavior, matrix modulation, and
therefore the overall outcome. This study is a first step, and
further research is need to keep improving the microtissue
model for cardiac fibrosis to fully develop this high potential
system into a controllable and reliable screening tool.
Conclusion
An in vitro tissue model is always a simplified reproduction
that can never reach the complexity found in native tissue. It is
exactly this simplicity that allows us to separately study and
understand the different aspects of a complex condition such
as cardiac fibrosis. In this study, we mimicked several aspects
of cardiac fibrosis by increasing either the collagen content or
the fibroblast density in our tissue model of cardiac fibrosis. In
this way, we were able to study the effect of these aspects on
cardiomyocyte functionality individually, which is not possi-
ble in vivo, and showed that increased fibroblast density has a
more detrimental effect on cardiomyocyte functionality than
increased collagen content. Because our tissue model can be
easily adapted to mimic other aspects of cardiac fibrosis, we
anticipate that it can be more widely used to gain further
insight into the mechanisms behind cardiac fibrosis and con-
tribute to development and testing of new anti-fibrotic thera-
pies and thereby reduce in vivo testing.
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